PTJ
DGX icon

Paul Tudor Jones’s Quest Diagnostics DGX Stock Holding History

Paul Tudor Jones’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Buy
20,900
+200
+1% +$39.3K 0.01% 1367
2026
Q1 		$4.06M Buy
20,700
+17,200
+491% +$3.34M 0.01% 1303
2025
Q4 		$607K Sell
3,500
-11,400
-77% -$2.08M ﹤0.01% 2603
2025
Q3 		$2.84M Buy
14,900
+7,000
+89% +$1.24M ﹤0.01% 1576
2025
Q2 		$1.42M Buy
7,900
+1,700
+27% +$295K ﹤0.01% 1906
2025
Q1 		$1.05M Buy
+6,200
New +$1.02M ﹤0.01% 1778
2023
Q2 		– Sell
-4,300
Closed -$608K – 2531
2023
Q1 		$608K Sell
4,300
-400
-9% -$57.2K 0.01% 1507
2022
Q4 		$735K Sell
4,700
-1,800
-28% -$259K 0.01% 1322
2022
Q3 		$797K Buy
6,500
+3,400
+110% +$448K 0.02% 1071
2022
Q2 		$412K Buy
+3,100
New +$422K 0.01% 1386
2022
Q1 		– Sell
-1,800
Closed -$312K – 2149
2021
Q4 		$312K Sell
1,800
-18,500
-91% -$2.81M 0.01% 1811
2021
Q3 		$2.95M Buy
+20,300
New +$2.97M 0.05% 492

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Paul Tudor Jones's DGX Position: Q2 2026 in Review

Paul Tudor Jones sold out of Quest Diagnostics (DGX) in Q2 2026, closing a stake of 18,225 shares — an estimated $3.58M sold.

Paul Tudor Jones first reported a position in DGX in Q3 2013 and held it in 27 quarters. The position peaked at $23.5M in Q1 2014. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Paul Tudor Jones reported no remaining Quest Diagnostics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 18,225 Quest Diagnostics shares in Q2 2026, an estimated $3.58M.
  • Paul Tudor Jones first reported a position in Quest Diagnostics in Q3 2013 and held it in 27 quarters.
  • Paul Tudor Jones's Quest Diagnostics position peaked at $23.5M in Q1 2014.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.